Our Company

We are a GI-focused company with products in development to treat serious conditions that affect patients and for which there are limited treatment options today.

Our Pipeline

Our pipeline consists of two late-stage therapies: Fexuprazan, for the treatment of erosive esophagitis (EE), and NG101, for the treatment
of gastroparesis.

Advancing the Treatment
of Serious GI Disorders

Neurogastrx, Inc. is a privately held, late clinical-stage biopharmaceutical company that is focused on identifying and developing therapies for patients suffering from serious gastrointestinal (GI) diseases.